COVID‐19 in patients with cutaneous immune‐mediated diseases in The Netherlands: real‐world observational data
Open Access
- 1 November 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (3) , E173-E176
Abstract
Literature about COVID‐19 infections in patients with chronic inflammatory (skin) diseases treated with or without systemic therapy is scarce and controversial.1‐6 Therefore, we aimed to investigate the incidence and clinical course of COVID‐19 related symptoms and the effect on clinical and psychological symptoms in patients with atopic dermatitis (AD) and psoriasis vulgaris (PsO).Keywords
This publication has 7 references indexed in Scilit:
- The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countriesPLOS ONE, 2020
- Evolution of COVID‐19 infection in four psoriatic patients treated with biological drugsJournal of the European Academy of Dermatology and Venereology, 2020
- The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experienceBritish Journal of Dermatology, 2020
- Should biologics for psoriasis be interrupted in the era of COVID-19?Journal of the American Academy of Dermatology, 2020
- Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020Eurosurveillance, 2020
- Should patients stop their biologic treatment during the COVID-19 pandemicJournal of Dermatological Treatment, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020